ESR1 and lung carcinoma: Recently, Hamilton et al. utilized a quantitative high-throughput screening of approved drugs, and identified the ER antagonist, fulvestrant, as being capable of reducing the mesenchymal features of lung cancer cells and sensitize to the cytotoxic effect of the chemotherapy [93].